International: +1-347-960-6455
Familial Adenomatous Polyposis (FAP) Therapeutics - Pipeline Analysis 2018

Familial Adenomatous Polyposis (FAP) Therapeutics - Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

Report Code: PP10025 Report Type: Indication Pipeline Reports Available format: 
Therapeutic Area(s): Gastroenterology
Select License Type

Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated FAP (AFAP), Gardner syndrome, and Turcot syndrome. The risk factors associated with FAP are obesity, physical inactivity, smoking, high alcohol and red meat consumption. TherapyX Inc. is in the process of developing FAPXIL as a small molecule with oral route of administration for the treatment of FAP. Other than this Cellix Bio Private Limited is also in the process of drug development for FAP.

  • The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
  • Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.